The UAB Cancer Center has received a $29 million National Cancer Institute renewal grant and is re-designated as “comprehensive” with an outstanding rating as a leader in advancing cancer research and care.
Cystic fibrosis lung cells were restored to 50 percent of healthy function in work that provides the first evidence that novel therapeutic strategies for human patients can be identified based on yeast studies.
Identifying a stable outlook and UAB’s very strong enterprise and financial profile, S&P Global Ratings has raised its rating on various series of general revenue bonds issued by The University of Alabama System Board of Trustees on behalf of UAB.
Longtime VP for Research and Economic Development Richard B. Marchase, Ph.D., plans to retire at the end of 2016. During his tenure, UAB annual research expenditures grew from $331 million to $510 million.
Results show that JAK/STAT pathway inhibitors may be a new class of therapeutic treatments for patients with Parkinson’s disease. Acting by reducing inflammation, they prevent neurodegeneration in animal models and may be an important new approach to slow progression of the disease.